THURSDAY, Oct. 27, 2022 (HealthDay News) -- For highly selected patients with breast cancer, eliminating surgery may be feasible for neoadjuvant systemic therapy (NST) responders identified with an image-guided vacuum-assisted core biopsy (VACB), according to a study published online Oct. 25 in The Lancet Oncology.
Henry M. Kuerer, M.D., from The University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a multicenter phase 2 trial in seven centers in the United States involving women aged 40 years or older with unicentric cT1-2N0-1M0 triple-negative breast cancer or human epidermal growth factor receptor 2 (HER2)-positive breast cancer and a residual breast lesion less than 2 cm on imaging after clinically standard NST. Patients had one biopsy obtained by 9G image-guided VACB of the tumor bed; breast surgery was omitted if no invasive or in-situ disease was identified, and patients underwent standard whole-breast radiotherapy plus a boost.
Fifty patients underwent VACB following NST: 21 and 29 had triple-negative and HER2-positive breast cancer, respectively. The researchers found that VACB identified 31 patients (62 percent) with a pathological complete response. No ipsilateral recurrences occurred in these patients at a median follow-up of 26.4 months. There were no serious biopsy-related adverse events or deaths related to treatment reported.
"While these results are remarkable and quite promising, it's important for patients to know this is the very beginning of a new type of treatment for select patients," Kuerer said in a statement. "Much longer follow-up and further studies will be necessary before this approach can be integrated into routine breast cancer care."
Several authors disclosed financial ties to the biopharmaceutical and publishing industries.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
- Disparities Examined in Perceptions of Breast Reconstruction ... ›
- Long-Term Outcomes of Breast Implants Explored - Consumer ... ›
- Biden Relaunches Cancer Moonshot Initiative - Consumer Health ... ›
- ASTRO: Ultra-High-Dose Radiotherapy Feasible for Extremity Bone Mets - Consumer Health News | HealthDay ›
- Shorter Regimen of Radiotherapy Safe for Soft Tissue Sarcoma - Consumer Health News | HealthDay ›
- Even Moderate Exercise Linked to Reduced Mortality After Breast Cancer - Consumer Health News | HealthDay ›
- SABCS: Updated Analysis Confirms Endocrine Therapy Effective With/Without Chemo - Consumer Health News | HealthDay ›
- Whole-Tumor Cell Culture Can Predict Drug Response in Breast Cancer - Consumer Health News | HealthDay ›
- Current Smokers at Breast Cancer Diagnosis Face Higher Death Risk - Consumer Health News | HealthDay ›
- Risk for Contralateral Breast Cancer Higher for Certain Pathogenic Variant Carriers - Consumer Health News | HealthDay ›
- Omission of Radiotherapy After Breast-Conserving Surgery Explored - Consumer Health News | HealthDay ›
- Survival Rate Lower for Surgery Nine Weeks or More After Breast Cancer Diagnosis - Consumer Health News | HealthDay ›
- Anatomic Stage, Receptor Status Influence Timing of Breast Cancer Recurrence - Consumer Health News | HealthDay ›